Agile Therapeutics Announces FDA Extension of Twirla® NDA Review Period
Agile Therapeutics, Inc. (AGRX)
Last agile therapeutics, inc. earnings: 5/2 04:15 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.agiletherapeutics.com/investor-relations
Company Research
Source: GlobeNewswire
PRINCETON, N.J., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its review of the New Drug Application (NDA) of Twirla® (levonorgestrel/ethinyl estradiol) transdermal system, an investigational combined hormonal contraceptive patch, from November 16, 2019 to February 16, 2020. On October 30, 2019, the FDA’s Bone, Reproductive, and Urologic Drugs Advisory Committee (BRUDAC) met to discuss the benefits and risks of Twirla and voted 14 to 1, with one abstention, that the benefits of Twirla (AG200-15) in the prevention of pregnancy outweigh the risks to support approval. Although the FDA considers the non-binding recommendation of this panel, the final decision regarding the approval of the product is made by the FDA alone. After the BRUDAC meeting, at the FDA’s request, Agile submitted additio
Show less
Read more
Impact Snapshot
Event Time:
AGRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AGRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AGRX alerts
High impacting Agile Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AGRX
News
- Agile Therapeutics, Inc. (NASDAQ: AGRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Agile Therapeutics, Inc. (NASDAQ: AGRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Agile Therapeutics, Inc. (NASDAQ: AGRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Agile Therapeutics, Inc. (NASDAQ: AGRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Agile Therapeutics, Inc. (NASDAQ:AGRX) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
AGRX
Earnings
- 11/9/23 - Beat
AGRX
Sec Filings
- 4/29/24 - Form 10-K/A
- 4/9/24 - Form 8-K
- 3/28/24 - Form 10-K
- AGRX's page on the SEC website